Business Wire

GLORY-GLOBAL-SOLUTIONS

31.1.2020 12:40:09 CET | Business Wire | Press release

Share
Acrelec Group SAS Welcomes Glory Ltd as Major Investor

Glory Global Solutions (International) Ltd , a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced plans for a significant investment in Acrelec Group SAS , a leader in responsive self-service solutions for the Quick Service Restaurant and retail industries.

Headquartered in Saint-Thibault-des-Vignes, France with operations in a further 14 countries, Acrelec focusses on developing people-centred experiences through self-service kiosks, digital signage as well as mobile ordering and collection solutions. In addition to the front of store solutions, the company offers “whole process automation” solutions including Internet of Things data analytics, IVR, visual assessment, external data integration, and the application of AI-generated rules to drive kitchen and process optimization for Quick Service Restaurants.

With over 40,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurants and retail brands among its customers. Speaking about the investment, Akihiro Harada, Chief Executive Officer at Glory Global Solutions said, “We have been working with the Acrelec team for a number of years and we recognised that there was a strong fit in our cultures and ambitions as well as complementary solutions that we bring to market. We see an increasing trend where consumers want to take more control over their in-store shopping and dining experiences. Acrelec offers consumers this control, through personally and contextually responsive self-service solutions. Our investment in Acrelec will help accelerate their pace of innovation to capitalize on this trend. We will also work together to ensure continued choice in customer payment, including the integration of Glory’s cash automation solutions to extend the range of payment options for consumers using Acrelec self-order and pay kiosks.”

Motozumi Miwa, President of GLORY Ltd, said: “Our investment in Acrelec is another step in the execution of GLORY’s Long-Term Vision 2028. Acrelec’s success in self-service kiosks, click and collect solutions, and drive-through service optimization, together with their expertise in IoT and artificial intelligence, are directly aligned with Glory’s diversification and growth strategy.”

Jacques Mangeot, Co-CEO of Acrelec commented, “Today’s investment by Glory will power the next exciting step for our company and represents a great opportunity for our customers and for our team. After many years of continuous effort to answer the in-store digital needs, we are ready to drive forward the deployment of our innovative next generation ‘’smart-store’’ solutions. Our stylish, high-quality hardware will benefit from a complete suite of innovative AI software that increases revenues and leverages speed of service.”

Co-CEO Jalel Souissi adds “This investment is a strong endorsement of our business direction. We know that partnering with the highly respected Glory Group will be reassuring for our extraordinary, world-leading customers, who can be certain Acrelec will continue to serve them with passion, devotion, and continuous innovation. Glory’s approach to the investment is also a fantastic opportunity for our team members, who will be enriched by new experiences and projects while they continue to live the Acrelec values of agility, customer proximity and innovation that have made us successful.”

Glory’s investment in Acrelec is subject to review by Acrelec’s employee representatives, and applicable competition authorities.

- ENDS -

About ACRELEC
Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, we develop and integrate new platforms that increase customer engagement, optimize efficiency and improve operations.

Our 900 employees around the globe collaborate with our customers and partners to design, create and build the world’s leading smart stores. Never satisfied with the status quo, our passion is in delivering breakthroughs that drive business results.

About GLORY
As a global leader in cash technology solutions, we provide the financial, retail, cash center and gaming industries with confidence that their cash is protected and always working to help build a stronger business.

Our cash automation technologies and process engineering services help businesses in more than 100 countries optimize the handling, movement and management of cash. While we span the globe, we personally engage with each customer to address their unique challenges and goals — enhancing staff efficiency, reducing operating costs and enabling a more rewarding customer experience.

Employing over 10,000 professionals worldwide with dedicated R&D and manufacturing facilities worldwide, GLORY is built on a rich customer-focused, technology-driven heritage spanning almost a hundred years.

For further information please visit www.glory-global.com or follow us on Twitter: http://twitter.com/glory_global .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye